PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no sons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION IS STATEMENT BY

(use as many sheets as necessary

Sheet 1 of 9

Complete if Known **Application Number** 10/601,656 Filing Date June 20, 2003 First Named Inventor Cham Group Art Unit 1623-1648 **Examiner Name** Not yet Assigned Chen Attorney Docket Number 13131-0310 (44378/282108)

U.S. PATENT DOCUMENTS							
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where	
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	
SBC	1	3,647,624		Evenson	03-07-1972		
1	2	3,958,939		Jones	05-25-1976		
	3	3,983,008		Shinozaki et al.	09-28-1976		
	4	3,989,466		Pan	11-02-1976		
	5	4,025,423		Stonner et al.	05-24-1977		
	6	4,103,685		Lupien et al.	08-01-1978	-	
	7	4,124,509		Iijima et al.	11-07-1978		
	8	4,234,317		Lucas et al.	11-18-1980		
	9	4,235,602		Meyer et al.	11-25-1980		
	10	4,258,010		Rozsa et al.	03-24-1981		
	11	4,350,156		Malchesky et al.	09-21-1982		
	12	4,391,711		Jackson et al.	07-05-1983		
	13	4,399,217		Holmquist et al.	08-16-1983		
	14	4,402,940		Nose et al.	09-16-1983		
	15	4,435,289		Breslau	03-06-1984		
	16	4,463,988		Bouck et al.	08-07-1984		
	17	4,645,512		Johns	02-24-1987		
	18	4,647,280		Maaskant et al.	03-03-1987		
	19	4,648,974		Rosskopf et al.	03-10-1987		
	20	4,668,398		Silvis	05-26-1987		
	21	4,671,909		Torobin	09-09-1987		
	22	4,676,905		Nagao et al.	06-30-1987		
	23	4,677,057		Curtiss et al.	06-30-1987		
	24	4,680,320		Uku et al.	07-14-1987		
	25	4,696,670		Ohnishi et al.	09-29-1987		
	26	4,775,483		Mookerjea et al.	10-04-1988		
	27	4,832,034		Pizziconi et al.	05-23-1989		
	28	4,836,928		Aoyagi et al.	06-06-1989		
	29	4,879,037		Utzinger	11-07-1989		
	30	4,908,354		Seidel et al.	03-13-1990		
	31	4,909,942		Sato et al.	03-20-1990		
	32	4,935,204		Seidel et al.	06-19-1990		
	33	4,966,709		Nose et al.	10-30-1990		
	34	4,970,144		Fareed et al.	11-13-1990	<u> </u>	
	35	5,026,479		Bikson et al.	06-25-1991		
	36	5,080,796		Nose et al.	01-14-1992		
	37	5,089,602		Isliker et al.	02-18-1992		
	38	5,112,956		Tang et al.	05-12-1992	·	
	39	5,126,240		Curtiss	03-30-1992		
<u> </u>	40	5,128,318		Levine et al.	07-07-1992		

	Examiner Signature	Stay B. Cher	Date Considered	12/2/2004
--	-----------------------	--------------	--------------------	-----------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 2

	nplete if Known
Application Number	10/601,656
Filing Date	June 20, 2003
First Named Inventor	Cham
Group Art Unit	1623-1648
Examiner Name	Not yet Assigned Chen
Attorney Docket Number	13131-0310 (44378/282108)

U.S. PATENT DOCUMENTS						
U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where		
Examiner Initials	Cite No.	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear
SAR	41	5,152,743		Gorsuch et al.	10-06-1992	
	42	5,187,010		Parham et al.	02-16-1993	
	43	5,203,778		Boehringer	04-20-1993	
	44	5,211,850		Shettigar et al.	05-18-1993	
	45	5,236,644		Parham et al.	08-17-1993	
_	46	5,258,149		Parham et al.	11-02-1993	
	47	5,279,540		Davidson	01-18-1994	
	48	5,301,694		Raymond et al.	04-12-1994	
	49	5,354,262		Boehringer et al.	10-11-1994	
	50	5,391,143		Kensey	02-21-1995	
	51	5,393,429		Nakayama et al.	02-28-1995	
	52	5,401,415		Rauh et al.	03-28-1995	
	53	5,401,466		Foltz et al.	03-28-1995	
	54	5,418,061		Parham et al.	05-23-1995	
	55	5,424,068		Filip	06-13-1995	
	56	5,476,715		Otto	12-19-1995	
	57	5,496,637		Parham et al.	03-05-1996	
	58	5,523,096		Okarma et al.	06-04-1996	
	59	5,634,893		Rishton	06-03-1997	
	60	5,637,224		Sirkar et al.	06-10-1997	
	61	5,652,339		Lerch et al.	07-29-1997	
_ i _ [62	5,679,260		Boos et al.	10-21-1997	
	63	5,707,673		Prevost et al.	01-13-1998	
	64	5,753,227		Strahilevitz	05-19-1998	
	65	5,855,782		Falkenhagen et al.	01-05-1999	
	66	5,858,238		McRea et al.	01-12-1999	
	67	5,919,369		Ash	07-06-1999	
	68	5,948,441		Lenk et al.	09-09-1999	
	69	5,962,322		Kozarsky et al.	10-05-1999	
	70	5,980,478		Gorsuch et al.	11-09-1999	
	71	6,004,925		Dasseux et al.	12-21-1999	·
	72	6,022,333		Kensev	02-28-2000	<u> </u>
	73	6,037,323		Dasseux et al.	03-14-2000	
	74	6,037,458		Hirai et al.	03-14-2000	
	75	6,039,946		Strahilevitz	03-21-2000	
	76	6,046,166		Dasseux et al.	04-04-2000	
	77	6,080,778		Yankner et al.	06-27-2000	
	78	6,127,370		Smith et al.	10-03-2000	
V	79	6,139,746		Kopf	10-31-2000	

Examiner Signature Date Considered 12/2/
--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3

	mation unless it contains a valid OMB control number
Coi	nplete if Known
Application Number	10/601,656
Filing Date	June 20, 2003
First Named Inventor	Cham
Group Art Unit	1623 1648
Examiner Name	Not yet Assigned Chen
Attorney Docket Number	13131-0310 (44378/282108)

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	U.S. Patent Do	Curnent Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
80x	80	6,156,727		Garber et al.	12-05-2000		
	81	6,171,373		Park et al.	01-09-2001		
	82	6,193,891		Kent et al.	02-27-2001		
	83	6,264,623		Strahilevitz	07-24-2001		
	84	6,309,550		Iverson et al.	10-30-2001		
	85	6,337,368		Kobayashi et al.	01-08-2002		
	86	6,440,387		Yankner et al.	08-27-2002		
	87	6,472,421		Wolozin	10-29-2002		
	88	6,605,588		Lees et al.	08-12-2003		
	89	6,706,008		Vishnoi et al.	03-16-2004		
	90	2001/0028895		Bisgaier et al.	10-11-2001		
	91	2002/0055529		Bisgaier et al.	05-09-2002		
	92	2002/0081263		Yankner et al.	06-27-2002		
	93	2002/0107173		Friedhoff et al.	08-08-2002		
	94	2002/0183379		Yankner et al.	12-05-2002		
	95	2002/0188012		Bisgaier et al.	12-12-2002		
V	96	2003/0018013		Dasseux et al.	01-23-2003		

Examiner	Stach	R Cha	Date	12/2/2011
Signature	May	D. CHEC	Considered	12/2/3004

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OM8 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4

o to respond to a collection or into	region dilless it contains a valid OWD courtoi infumbet
Cor	nplete if Known
Application Number	10/601,656
Filing Date	June 20, 2003
First Named Inventor	Cham
Group Art Unit	1623 1648
Examiner Name	Not yet Assigned Chen
Attorney Docket Number	13131-0310 (44378/282108)

				FORE	IGN PATENT DOCUMEN	JTS		_
	T		Foreign Patent D	ocument	The state of the s	Date of Publication of	Pages, Columns, Lines,	т-
Examiner Initials	Cite No.1	Office ³		Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
8BC	97	CN	1189378		Central Blood Ban ChangChun CI	08-05-1998	Abstract Only / yrsc	Ţ
	98	DE	29 44 138		Technicon Gmbh	06-11-1981		╁╌
	99	DE	31 18 072	Al	Heuck	11-25-1982		-
SAL		DE	32 13 390	Al	Schurek, et al.	10-20-1983	Abs. inh size	F
- 1,7-	101	DE	33 10 263	AI	Freschius AG	09-27-1984	ANS. UNIL SIDE	├
spe	102	EP	0 036 283	A2	Davy Mckee Minerals & Metals	09-23-1981		F
	103	EP	0 267 471	Al	Pennwalt Corporation	05-19-1988		-
	104	FR	2 571 971	A1	Haas Thierry	04-25-1986	Abs. only spe	-
	105	JP	127104		Shinriyoushiyo	01-10-1980	1	\vdash
	106	JР	277303		Tenkaidou	10-26-1993		
	107	SU	1116396	A	Mosc. Med Inst. Pirog	09-30-1984		-
	108	SU	1204224	Α	Kazan Chem. Tech Inst.	01-15-1986		\vdash
	109	SU	1752187	A3	Sigalov	07-30-1992	Abstract only	_
	110	wo	88/09345	Al	The Rogosin Institute	12-01-1988	1 to sit dot of ity	_
	111	WO	95/03840	Al	The University of Queensland	02-09-1995		
	112	wo	99/38498	A1	Warner-Lambert Company	08-05-1999		
	113					00 05-1777		_
	114	wo	01/56579	Al	Esperion Therapeutics, Inc.	08-09-2001		
	115	wo	02/010768	A3	Regents of University of California	02-07-2002		
	116	wo	02/062824	A2	Andrx Corporation	08-15-2002		
V	117	wo	02/30863	A2	Esperion Therapeutics, Inc.	04-18-2002		
								_
								_
								_
								_
			· · · · · · · · · · · · · · · · · · ·					_
						 		—

Examiner Signature Date Considered 12/2/2000
--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

PTC/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known			
Substitute for Form 1449/A/PTO				Application Number	10/601,656		
	INIEODMAT	IOI	N DISCLOSURE	Filing Date	June 20, 2003		
				First Named Inventor	Cham		
			BY APPLICANT	Group Art Unit	1623 1648		
(use as many sheets as necessary				Examiner Name	Not yet Assigned ("inen		
Sheet	5	of	9	Attorney Docket Number	13131-0310 (44378/282108)		

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cile No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	118	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing	
SPC		Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)	
	119	Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles,	
		76 (14), 6919-6928. (July 2002)	
	120	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Distribution of Apo A-I-Containing HDL Subpopulations in Patients with	
		Coronary Heart Disease, 2670-2676. (December 1, 2000)	
	121	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Presence and Formation of 'Free Apolipoprotein A-I-Like' Particles in Human	
		Piasma, 15, 1419-1423. (1995)	
	122	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Role of Free Apolipoprotein A-I in Cholesterol Efflux, 17, 1630-1636. (1997)	
	123	Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in	
		Cholesterol-Fed Rabbits, 60, 455-461. (1989)	
	124	Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in	
		the Cholesterol-Fed Rabbit, 85, 1234-1241. (1990)	
	125	Barrans et al., Biochimica et Biophysica Acta, Pre-β HDL: Structure and Metabolism, 1300, 73-85. (1996)	
	126	Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (November 9, 2001)	
	127	Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human	
		serum , 14, 119-125. (abstract only) (June 1981)	
+	128	Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as	
		Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976)	
	129	Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of a- and \(\beta\)-Lipoproteins as a Result of Plasma	-
		Delipidation, 22, 305-309. (1976)	
J	130	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	

Examiner Signature	Stay 7 (Iron	Date	12/2/2004
Signature	TE COOL	Considered	13/3/2009

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to response

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 6

ed to respond to a contection of intoli	mation unless it contains a valid OMP control infiniter
Cor	mplete if Known
Application Number	10/601,656
Filing Date	June 20, 2003
First Named Inventor	Cham
Group Art Unit	1623 1648
Examiner Name	Not yet Assigned Chen
Attorney Docket Number	13131-0310 (44378/282108)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
890	131	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
	132	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
	133	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid Concentrations and Mobilisation of Lipid from Liver and Aorta, 13, 25-32. (1994)	-
	134	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns, 11, 61-70. (1996)	
	135	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
	136	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
	137	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49, 109-113. (1973)	
	138	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
·	139	Cooper, Drugs Aging, Dietary Lipids in the Aetiology of Alzheimer's Disease: Implications for Therapy, 20 (6), 399-418. (abstract only) (2003)	
	140	Cruzado et al., Analytical Biochemistry, Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by Capillary Electrophoresis, 14 (7), 100-109. (1996)	
	141	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	
	142	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH: First Clinical Application of the HELP System, 65, 161-168. (1987)	
1	143	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)	

Examiner Signature	Stack B. Che	Date Considered	12/	2/2004
		Considered		2/00/

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Lo a collection of information unless it contains a valid OMB control number.

	Choci inc i aperwork Reduction Act of 1995, no persons are re	equired to respond to a collection of trifor	mation unless it contains a valid OMB control number	
		Complete if Known		
Substitute f	or Form 1449/A/PTO	Application Number	10/601,656	
i i	NFORMATION DISCLOSURE	Filing Date	June 20, 2003	
		First Named Inventor	Cham	
,	STATEMENT BY APPLICANT	Group Art Unit	1623 1648	
	(use as many sheets as necessary	Examiner Name	Not yet Assigned Chen	
Sheet	7 of 9	Attorney Docket Number	13131-0310 (44378/282108)	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	144	Golde et al., Drug Discovery Today, Cholesterol Modulation as an Emerging Strategy for the Treatment of Alzheimer's	
SBC		Disease, 6 (20), 1049-1055. (abstract only) (October 15, 2001)	
	145	Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68.	1
		(1968)	
	146	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as	
		Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)	
	147	Jackson et al., Biochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High	†
		Density Lipoproteins, 420, 342-349. (1976)	
	148	Koizumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid	
		Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)	
	149	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in	
		Hypercholesteraemic Chickens after Trealment with a Newly Developed Extracorpreal Lipid Elimination. (May 13, 1992)	
	150	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in	
		Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)	
	151	Koudinov et al., Clin Chim Acta, Alzheimer's Amyloid Beta Interaction with Normal Human Plasma High Density Lipoprotein:	
		Association with Apolipoprotein and Lipids, 270 (2), 75-84. (abstract only) (February 23, 1999)	
	152	Koudinov et al., Cell Biol Int., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, 21	
		(5), 265-71. (abstract only) (May 1997)	
	153	Koudinov et al., Biochem Biophys Res Commun, Biochemical Characterization of Alzheimer's Soluble Amyloid Beta Protein in	
		Human Cerebrospinal Fluid: Association with High Density Lipoproteins, 223 (3), 592-7. (abstract only) (June 25, 1999)	
	154	Koudinov et al., Science, Cholesterol's Role in Synapse Formation, 294, 2213. (November 9, 2001)	
	155	Koudinova et al., Soc. Neuroscience Abstract Viewer and Itinerary Planner, Amyloid Beta, Neural Lipids, Cholesterol and	
		Alzheimer's Disease - Abstract No, 21.10. (2002)	
	156	Lipid Sciences, http://www.lipidsciences.com/lechnology.html, Lipid Technology, 1-4. (August 25, 2001)	
₩ .			

	Examiner Signature	Stay B. Cher	Date Considered	12/2	12004
--	-----------------------	--------------	--------------------	------	-------

PTO/SB/088 (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control purpose Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 8 of 9

	maderi diffess it contains a valid OMB control number
Cor	nplete if Known
Application Number	10/601,656
Filing Date	June 20, 2003
First Named Inventor	Cham
Group Art Unit	1623 1648
Examiner Name	Not yet Assigned Chen
Attorney Docket Number	13131-0310 (44378/282108)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T -
	157	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-	
SPC		Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)	
	158	Mauch et al., Science, CNS Synaptogenesis Promoted by Glia-Derived Cholesterol, 294, 1354-1357. (November 9, 2001)	
	159	Moya et al., Arteriosclerosis and Thrombosis, A Cell Culture System for Screening Human Serum for Ability to Promote	H
		Cellular Cholesterol Efflux, 14 (7), 1056-1065. (July 1994)	
	160	Okazaki et al., Journal of Chromatography, Biomedical Applications, Improved High-Performance Liquid Chromatographic	┢
		Method for the Determination of Apolopoproteins in Serum High-Density Lipoproteins, 430, 135-142. (1988)	
	161	Refolo et al., Soc. Neuroscience Abstracts, Cholesterol Metabolism: A Potential Target for Alzheimer's Disease Therapy, 27	r
		(2), 1518. (abstract only) (2001)	
	162	Robern et al., Experientia, The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of	
		High Density Lipoproteins, 38, 437-439. (1982)	
1	163	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in	H
		Plasma or Serum, 13, 769-772. (1967)	
	164	Scanu et al., Analytical Biochemistry, Sclubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the	
		Serum Very Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum	
		Lipoproteins, 44, 576-588. (1971)	
1 1	165	Segrest et al., Journal of Biological Chemistry, A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density	
		Lipoprotein, 274 (45), 31755-31758. (November 5, 1999)	
1 1	166	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human	
		Mononuclear Leukocytes, 20, 413-416. (1979)	
1 1	167	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35,	_
		41-49. (1980)	
1	168	Thompson, et al., Lancet (LOS), Plasma Exchange in the Management of Homozygous Familial Hypercholesterolaemia, 1,	-
V		1208-1211. (1975)	

Examiner Stay B. Cher	Date Considered	12/2/2004
-----------------------	--------------------	-----------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/601,656 Filing Date June 20, 2003 **INFORMATION DISCLOSURE** First Named Inventor Cham STATEMENT BY APPLICANT Group Art Unit 1623 1648 (use as many sheets as necessary Examiner Name Not yet Assigned Chen Sheet 9 Attorney Docket Number 13131-0310 (44378/282108)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	 .
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
SK	169	Williams, et al., Proc. Natl. Acad. Sci. USA, Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic,	
		Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis, 85, 242-246. (1988)	
	170	Williams et al., Biochim. Biophys. Act., Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein , 875 (2), 183-194.	
		(February 12, 1986)	
	171	Wong, et al, Journal of Lipid Research, Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol	
		extraction, 24, 666-669. (1983)	
	172	Wormser, Henry, PSC3110 - Fall Semester 2002, Lipids.	
	150		
	173	Yokoyama, et al., Arteriosclerosis, Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial	
		Hypercholesterolemia, 5, 613-622. (1985)	
	174	Yoshidome et al., Artif Organs, Serum Amyloid A and P Protein Levels are Lowered by Dextran Sulfate Cellulose Low-Density	
		Lipoprotein Apheresis, 22 (2), 144-148. (1998)	•
$\sqrt{}$	175	Zhang et al., Journal of Lipid Research, Characterization of phospholipids in a pre-alpha HDL: Selective Phospholipid Efflux	
		with Apolipoprotein A-I , 39, 1601-1607. (1998)	
1			
	-		

Examiner Signature	Hay B Chen	Date Considered	12/2	12004
	•		t t	,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet	1	of	2	
		<u> </u>	-	

Cor	nplete if Known			
Application Number	Not yet assigned			
Filing Date	June 20, 2003			
First Named Inventor BILL E. CHAM				
Group Art Unit	Not yet assigned 1648			
Examiner Name	Not yet assigned Chen			
Attorney Docket Number	13131-0310 (44378-282108)			

			U	S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	Number	ent Document Kind Code ¹ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Sec	1	4,481,189		PRINCE	11-06-1984	
	2	4,522,809		ADAMOWICZ, et al.	06-11-1985	
	3	4,540,401		MARTEN	09-10-1985	
	4	4,540,573		NEURATH, et al.	09-10-1985	
	5	4,591,505		PRINCE	05-27-1986	
	6	4,613,501		HOROWITZ .	09-23-1986	
	7	4,615,886		PURCELL, et al.	10-07-1986	
	8	4,643,718		MARTEN	02-17-1987	
	9	4,895,558		CHAM .	02-23-1990	
	10	4,909,940		HOROWITZ, et al.	03-20-1990	
	11	4,923,439		SEIDEL, et al.	05-08-1990	
	12	5,116,307		COLLINS	05-26-1992	· · · · · · · · · · · · · · · · · · ·
	13	5,256,767		SALK, et al.	10-26-1993	
	14	5,419,759		NAFICY	05-30-1995	
	15	5,484,396		NAFICY	02-16-1996	
	16	5,698,432		OXFORD	12-16-1997	
	17	5,719,194		MANN, et al.	02-17-1998	
	18	5,744,038		CHAM	04-28-1998	
	19	5,853,725		SALK et al.	12-29-1998	
	20	5,877,005		CASTOR	03-02-1999	···
	21	5,885,578		SALK et al.	03-23-1999	
	22	5,895,650		SALK et al.	04-20-1999	
	23	5,911,698		СНАМ	06-15-1999	
	24	5,916,806		SALK et al.	06-29-1999	
	25	5,928,930		SALK et al.	07-27-1999	
	26	6,017,543		SALK et al.	01-25-2000	
	27	6,136,321		BARRETT, et al.	10-24-2000	
V						

			FOF	REIGN PATENT DOCUME	NTS		
Examiner Initials	Cite No.1	Foreign Patent Do	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
Spe	28	CA 1271708		REINHARD, et al.	07-17-1990		
SBC.	29	WO 01/45718		ARUBA INTERNATIONAL PTY LTD	06-28-2001		

	Examiner Signature	Stary S. Cho.	Date Considered	12/3	13004
--	-----------------------	---------------	--------------------	------	-------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for Form 1449/A/PTO **Application Number** Not yet assigned Filing Date June 20, 2003 INFORMATION DISCLOSURE First Named Inventor BILL E. CHAM STATEMENT BY APPLICANT Group Art Unit Not yet assigned 1648 (use as many sheets as necessary Examiner Name Not yet assigned Chen Sheet 2 of 2 Attorney Docket Number 13131-0310 (44378-282108)

		······	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	Sec	30	AGNESE, S.T., et al., "Evaluation of Four Reagents for Dilipidation of Serum," Clin Biochem (1983) Apr., Vol. 16, No. 2, pp. 98-100.	
		31	CHAM, BILL E., et al., "Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals," Journal of Clinical Apheresis, Vol. 10, 1995, pp. 61-69.	
		32	CHAM, BILL E., et al., "A solvent system for delipidation of plasma or serum without protein precipitation," Journal of Lipid Research, Vol. 17, 1976, pp. 176-181.	
		33	DEVA, A.K., et al., "Establishment of an in-use testing method for evaluating disinfection of surgical instruments using the duck hepatitis B model," J. Hosp. Infect., (1996) June, Vol. 22, No. 2, pp. 119-130, Abstract only.	
		34	FEINSTONE, STEPHEN M., et al., "Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform," Infection and Immunity, August 1983, Vol. 41, No. 2, pp. 816-821.	
	\bigvee	35	HOROWITZ, B., et al., "Viral safety of solvent/detergent-treated blood products," Blood Coagulation and Fibrinolysis," Vol. 5, Suppl. 3, 1994, pp. S21-S28.	
Spe		36	KLIMOV, A.N. et al., "Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized Plasma into the Body as a Possible Means to Treat Atherosclerosis", Russian Journal Kardiologiia, Vol. 18, No. 6, pp. 23-29 (1978).	~
OK considered	8Bc	37	NGU, V.A., "Chronic Infections from the Perspective of Evolution: a Hypothesis", Medical Hypotheses, Vol. 42, pp. 81-88 (1994).	
12/3/2		38/	NGU, V.A., "Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain Enveloped Viruses Using Modified Viral Antigens", <i>Medical Hypotheses</i> , Vol. 39, pp. 17-21 (1992).	
		39	NGU, V.A., "The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune response to the virus", <i>Medical Hypotheses</i> , Vol. 48, pp. 517-521 (1997).	
	\downarrow	40	PARKER, THOMAS S., et al., "Plasma high density lipoprotein is increased in man when low density lipoprotein (LDL) is lowered by LDL-pheresis," Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 771-781, February 1986.	

Examiner Signature	StacyDa	Date Considered	12/2	12004
	71			

¹Unique citation designation number. ¹²Applicant is to place a check mark here if English language translation is attached.